Navigation Links
BioMed Realty Trust Declares Third Quarter 2009 Common Stock and Preferred Stock Dividends
Date:9/15/2009

SAN DIEGO, Sept. 15 /PRNewswire-FirstCall/ -- BioMed Realty Trust, Inc. (NYSE: BMR) today announced that its board of directors has declared a third quarter 2009 dividend of $0.11 per share of common stock. The dividend is equivalent to an annualized dividend of $0.44 per common share.

BioMed also announced that its board of directors has declared a dividend of $0.46094 per share of the company's 7.375% Series A Cumulative Redeemable Preferred Stock for the period from July 16, 2009 through October 15, 2009.

Both dividends are payable on October 15, 2009 to stockholders of record at the close of business on September 30, 2009.

About BioMed Realty Trust

BioMed Realty Trust, Inc. is a real estate investment trust (REIT) focused on Providing Real Estate to the Life Science Industry(R). The company's tenants primarily include biotechnology and pharmaceutical companies, scientific research institutions, government agencies and other entities involved in the life science industry. BioMed owns or has interests in 69 properties, representing 114 buildings with approximately 10.5 million rentable square feet. The company's properties are located predominantly in the major U.S. life science markets of Boston, San Diego, San Francisco, Seattle, Maryland, Pennsylvania and New York/New Jersey, which have well-established reputations as centers for scientific research. Additional information is available at www.biomedrealty.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 based on current expectations, forecasts and assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties include, without limitation: general risks affecting the real estate industry (including, without limitation, the inability to enter into or renew leases, dependence on tenants' financial condition, and competition from other developers, owners and operators of real estate); adverse economic or real estate developments in the life science industry or the company's target markets; risks associated with the availability and terms of financing, the use of debt to fund acquisitions and developments, and the ability to refinance indebtedness as it comes due; failure to manage effectively the company's growth and expansion into new markets, or to complete or integrate acquisitions and developments successfully; risks and uncertainties affecting property development and construction; risks associated with downturns in the national and local economies, increases in interest rates, and volatility in the securities markets; potential liability for uninsured losses and environmental contamination; risks associated with the company's potential failure to qualify as a REIT under the Internal Revenue Code of 1986, as amended, and possible adverse changes in tax and environmental laws; and risks associated with the company's dependence on key personnel whose continued service is not guaranteed. For a further list and description of such risks and uncertainties, see the reports filed by the company with the Securities and Exchange Commission, including the company's most recent annual report on Form 10-K and quarterly reports on Form 10-Q. The company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE BioMed Realty Trust, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Sponsor-A-Scientist: New Option to Fund Biomedical Research
2. Biomedical Research Centre developing enhanced cells as therapies
3. Environmental Tectonics Corporations BioMedical Systems Division Announces First BARA-MED(R) Monoplace Hyperbaric Chamber Sale in Romania
4. Collexis BiomedExperts.com Achieves 200,000 Registered Users
5. BioMed Realty Trust Commemorates Five-Year Anniversary as a Public Company
6. New test for safer biomedical research results
7. BioMed Realty Trust Reports Second Quarter 2009 Operating and Financial Results
8. LA BioMed President and CEO will be named president of the American Judicature Society
9. Successful Beginning for Wellstone Muscular Dystrophy Center at Boston Biomedical Research Institute
10. BioMed Realty Trust Completes $350 Million Financing for Center for Life Science Boston
11. BioMed Realty Trust Closes New $18 Million Secured Loan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... ... May 05, 2016 , ... Dental365 in Levittown opened just a few ... dentistry. Dental365 was established with the patient’s comfort and convenience in mind. ... high-quality, affordable dentistry while offering routine and walk-in emergency dental care 365 days a ...
(Date:5/4/2016)... ... May 05, 2016 , ... “Less than 15% of organizations nationwide can ... “As one of ten non-profit organizations to participate and complete the training, we are ... benefit is that for every $1 we invest in volunteer engagement, we can expect ...
(Date:5/4/2016)... ... May 04, 2016 , ... The manufacturer of the SOCKIT ... trainers to St. Jude Children’s Research Hospital to benefit families dealing with cancer ... designed to teach children how to kick a soccer ball correctly. The device ...
(Date:5/4/2016)... ... May 04, 2016 , ... NCPDP ... conference opened on Tuesday with Frank Luntz, sharing a dynamic, bi-partisan environmental scan ... a deep dive on NCPDP’s model solution to help stem the tide of ...
(Date:5/4/2016)... ... May 04, 2016 , ... The Lymphoma Research ... lymphoma research and serving the lymphoma community through a comprehensive series of education ... esteemed Quaker Ridge Golf Club in Scarsdale, New York on May 23, 2016 ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... JERUSALEM , May 4, 2016 ... University of Jerusalem announced today that it had ... BioTheryX, Inc. , developer of novel protein degradation ... the development and commercialization of drug candidates representing first-in-class ... the license were not disclosed. The novel ...
(Date:5/4/2016)... , May 4, 2016 ... addition of the  "Global Acute Myeloid Leukemia ...  report to their offering.       ... Acute Myeloid Leukemia Market and Competitive Landscape ... Myeloid Leukemia pipeline products, Acute Myeloid Leukemia ...
(Date:5/3/2016)... -- Research and Markets has announced the ... Market Outlook 2020" report to their offering. ... technology has improved significantly in past years due to ... coming years. Many cancer drugs have been developed by ... also expected to be developed with its help. They ...
Breaking Medicine Technology: